| 货号 | 物种 | 产品描述 | 蛋白结构 | 纯度 | 活性 |
|---|---|---|---|---|---|
| INR-H52Ha |
 Human |
Human Insulin R / CD220 (28-944) Protein, His Tag (SPR verified) |
 |
  |
  |
| 英文名称 | 中文名称 | 研发代码 | 研发阶段 | 公司 | 最早商品名 | 最早批准国家 | 最早适应症 | 最早批准公司 | 最早批准日期 | 适应症 | 临床试验 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rinsulin NPH (Geropharm) | 批准上市 | GEROPHARM | 糖尿病 | 详情 | |||||||
| Insulin degludec | 德谷胰岛素 | NN-1250; Insulin-454,NN1250 | 批准上市 | 诺和诺德 | Insulin degludec | 日本 | 糖尿病 | 诺和诺德 | 2012-09-28 00:00:00.0 | 糖尿病, 1型糖尿病, 2型糖尿病 | 详情 |
| Human insulin biosimilar (Square Pharmaceuticals) | 人胰岛素生物类似药 (Square Pharmaceuticals) | 批准上市 | Square Pharmaceuticals | 糖尿病 | |||||||
| Oral insulin (Generex Biotechnology) | 批准上市 | Generex Biotechnology Corporation, SciVac Ltd, PharmaBrand, DongSung Pharm | 1型糖尿病, 2型糖尿病 | ||||||||
| Recombinant human insulin (Shenzhen Kexing Biotech) | 重组人胰岛素注射液 | 批准上市 | 深圳科兴, 深圳科兴 | 糖尿病 | |||||||
| Insulin glargine biosimilar (Lilly/Boehringer Ingelheim) | 甘精胰岛素生物类似药 (Lilly/Boehringer Ingelheim) | LY-2963016; LY2963016-U-100; LY2963016-U-200,LY2963016 | 批准上市 | 礼来, 勃林格殷格翰 | insulin glargine | ema | Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. |
Eli Lilly Nederland B.V. | 2014-09-09 | 1型糖尿病, 2型糖尿病 | 详情 |
| Recombinant human insulin (SciGen) | 批准上市 | Generex Biotechnology Corporation, SciVac Ltd | 糖尿病 | ||||||||
| Human insulin biosimilar (MJ Biopharm) | 人胰岛素生物类似药 (MJ Biopharm) | 批准上市 | MJ Biopharm Pvt | 糖尿病 | |||||||
| Recombinant Human Insulin (Wanbang Pharma) | 重组人胰岛素（万邦生化） | 批准上市 | 万邦医药 | Recombinant Human Insulin Injection | cfda | 糖尿病 | 2015-08-25 | 糖尿病 | |||
| Insulin biosimilar (Julphar) | 胰岛素生物类似药 (Julphar) | 批准上市 | Julphar Gulf Pharmaceutical Industries | 糖尿病 | 详情 | ||||||
| Ceritinib | 色瑞替尼 | LDK-378; NVP-LDK378; NVP-LDK378-NX,LDK378,LDK 378 | 批准上市 | 诺华 | ZYKADIA | fda | 非小细胞肺癌 | NOVARTIS | 2014-04-29 | 非小细胞肺癌 | 详情 |
| Insulin human (rDNA origin, Novo Nordisk) | 人胰岛素（诺和诺德） | NN-729,NN729 | 批准上市 | 诺和诺德 | Mixtard 50/50 | hma | 糖尿病 | Novo Nordisk A/S Novo Alle DK-2880 Bagsv?rd |
1996-07-29 | 糖尿病 | 详情 |
| Isophane Protamine Recombinant Human Insulin Injection (Shenzhen Kexing Biotech) | 精蛋白重组人胰岛素注射液（深圳科兴） | 批准上市 | 深圳科兴 | 糖尿病 | |||||||
| Rosinsulin | 批准上市 | Medsintez | 糖尿病 | ||||||||
| Insulin glargine biosimilar (Incepta Pharmaceuticals) | 甘精胰岛素生物类似药 (Incepta Pharmaceuticals) | 批准上市 | Incepta Pharmaceuticals | 1型糖尿病, 2型糖尿病 | |||||||
| Insulin biosimilar (Harvest Moon Pharmaceuticals) | 胰岛素生物类似药 (Harvest Moon Pharmaceuticals) | 批准上市 | Harvest Moon | 糖尿病 | |||||||
| Insulin aspart | 门冬胰岛素 | NN-1218; INA-X14; Insulin X14 | 批准上市 | 诺和诺德 | insulin aspart | ema | NovoRapid is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. |
Novo Nordisk A/S | 1999-09-07 | 糖尿病 | 详情 |
| Insulin N biosimilar (Popular Pharmaceuticals) | 胰岛素生物类似药 (Popular Pharmaceuticals) | 批准上市 | Popular Pharmaceuticals | 糖尿病 | |||||||
| Insulin glargine biosimilar (LG Life Sciences) | 甘精胰岛素生物类似药 (LG Life Sciences) | 批准上市 | LG Life Sciences, Lupin | 1型糖尿病, 2型糖尿病 | |||||||
| Recombinant lispro insulin biosimilar (Gan & Lee) | 重组赖脯胰岛素生物类似药（甘李药业） | 批准上市 | 甘李生物 | Recombinant Lispro Insulin Injection | cfda | 糖尿病 | 2019-05-08 | 糖尿病 | 详情 | ||
| Insulin biosimilar (Popular Pharmaceuticals) | 胰岛素生物类似药 (Popular Pharmaceuticals) | 批准上市 | Popular Pharmaceuticals | 糖尿病 | |||||||
| Isophane Insulin | 低精蛋白锌胰岛素 | 批准上市 | 万邦医药 | Isophane Insulin Injection | cfda | 糖尿病 | 2015-08-25 | 糖尿病 | |||
| Recombinant human insulin (Incepta) | 重组人胰岛素（Incepta） | 批准上市 | Incepta Pharmaceuticals | 糖尿病 | |||||||
| Insulin lispro | 赖脯胰岛素 | LY-275585; Lys-B28; Pro-B29; LYSPRO; LY-900027 | 批准上市 | 礼来 | insulin lispro | ema | For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog is also indicated for the initial stabilisation of diabetes mellitus. < |
Eli Lilly Nederland B.V. | 1996-04-30 | 糖尿病 | 详情 |
| Recombinant human insulin (Biocon) | 批准上市 | Biocon | 糖尿病 | 详情 | |||||||
| Insulin human | HR-1799 | 批准上市 | Sanofi Deutschland | insulin human | ema | Diabetes mellitus where treatment with insulin is required. Insuman Rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisati |
Sanofi-aventis Deutschland GmbH | 1997-02-21 | 糖尿病, 糖尿病酮症酸中毒引起的脑水肿 | ||
| Insulin biosimilar (Sedico) | 胰岛素生物类似药 (Sedico) | 批准上市 | Sedico | 糖尿病 | |||||||
| Insulin degludec/Insulin aspart | 德谷胰岛素/门冬胰岛素 | NN-5401; NN-1045; NN-1250/Insulin aspart | 批准上市 | 诺和诺德 | Insulin degludec/Insulin aspart | 日本 | 糖尿病 | 诺和诺德 | 2012-12-25 00:00:00.0 | 糖尿病, 1型糖尿病, 2型糖尿病 | 详情 |
| Insulin detemir | 地特胰岛素 | NN-304 | 批准上市 | 诺和诺德 | Insulin detemir | ema | Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. |
Novo Nordisk A/S | 2004-06-01 | 1型糖尿病, 糖尿病 | 详情 |
| Recombinant insulin (Horizon Pharma/Ibatech) | 批准上市 | Savient Pharmaceuticals, Horizon, Ibatech Sp. zo.o | 1型糖尿病 | ||||||||
| Insulin degludec/Liraglutide | 德谷胰岛素/利拉鲁肽 | NN-9068,NN9068 | 批准上市 | 诺和诺德 | insulin degludec;liraglutide | ema | Xultophy is indicated for the treatment of adults with type-2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering 详情 |
||||
| Insulin glargine biosimilar (Wockhardt) | 甘精胰岛素生物类似药 (Wockhardt) | 批准上市 | Wockhardt | 糖尿病, 1型糖尿病, 2型糖尿病 | 详情 | ||||||
| Recombinant insulin glargine (Gan & Lee) | 重组甘精胰岛素（甘李药业） | 批准上市 | 甘李生物 | Recombinant Insulin Glargine Injection | cfda | 糖尿病 | 2015-02-03 | 糖尿病 | 详情 | ||
| Insulin glargine biosimilar (Getz Pharma) | 甘精胰岛素生物类似药 (Getz Pharma) | 批准上市 | Getz Pharma | 1型糖尿病, 2型糖尿病 | |||||||
| Insulin lispro biosimilar (Sanofi) | 赖脯胰岛素生物类似药（赛诺菲） | SAR-342434 | 批准上市 | 赛诺菲 | insulin lispro | ema | For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Insulin lispro Sanofi is also indicated for the initial stabilisation of diabetes |
sanofi-aventis groupe | 2017-07-18 | 糖尿病 | 详情 |
| Insulin glulisine | 谷赖胰岛素 | HMR-1964,HMR1964 | 批准上市 | 赛诺菲 | APIDRA | fda | 1型糖尿病, 糖尿病 | SANOFI AVENTIS US | 2004-04-16 | 1型糖尿病, 糖尿病 | 详情 |
| Insul 30/70 biosimilar (Popular Pharmaceuticals) | 批准上市 | Popular Pharmaceuticals | 1型糖尿病, 妊娠期糖尿病, 2型糖尿病 | ||||||||
| Bacitracin | 批准上市 | 辉瑞 | 细菌感染 | 详情 | |||||||
| Insulin glargine biosimilar (Biocon) | 甘精胰岛素生物类似药 (Biocon) | MYL-1501D | 批准上市 | Biocon BioPharmaceuticals, FUJIFILM Corporation, 迈兰制药 | 日本 | 糖尿病 | FUJIFILM Corporation | 2016-03-28 00:00:00.0 | 糖尿病 | 详情 | |
| Insulin glargine biosimilar (Merck Sharp & Dohme) | 甘精胰岛素生物类似药（默沙东） | MK-1293; SB-9 | 批准上市 | 三星Bioepis, 默沙东 | insulin glargine | ema | Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. |
Merck Sharp & Dohme B.V. | 2017-01-03 | 1型糖尿病, 2型糖尿病 | 详情 |
| Recombinant human insulin (Tonghua Dongbao Pharmaceutical) | 重组人胰岛素（通化东宝） | 批准上市 | 通化东宝 | Isophane Protamine Recombinant Human Insulin Injection | cfda | 糖尿病 | 2015-08-18 | 糖尿病 | 详情 | ||
| Insulin human (inhalation powder) | 人胰岛素 | SAR-439065,SAR439065 | 批准上市 | MannKind Corporation, 赛诺菲 | AFREZZA | fda | 糖尿病 | MANNKIND | 2014-06-27 | 糖尿病 | 详情 |
| Insulin human (rDNA origin, Lilly) | 人胰岛素（礼来） | S-3300; LY-041001; U-500R | 批准上市 | 礼来 | HUMULIN R PEN | fda | 糖尿病 | LILLY | 1982-10-28 | 糖尿病 | 详情 |
| Recombinant human insulin (United Laboratories International Holdings) | 批准上市 | 珠海联邦制药中山分公司 | Isophane Protamine Recombinant Human Insulin Injection | cfda | 糖尿病 | 2014-11-24 | 糖尿病 | ||||
| Insulin glargine | 甘精胰岛素 | Gla-100; Gla-300; HOE901-U300; Hoe-71GT; Hoe-901; U-300 | 批准上市 | 赛诺菲 | LANTUS SOLOSTAR | fda | 1型糖尿病, 2型糖尿病 | SANOFI AVENTIS US | 2000-04-20 | 糖尿病, 1型糖尿病, 2型糖尿病 | 详情 |
| Insulin biosimilar (Wockhardt) | 胰岛素生物类似药 (Wockhardt) | 批准上市 | Wockhardt | 1型糖尿病 | 详情 | ||||||
| Insulin glargine/Lixisenatide | HOE-901/AVE-0010 | 批准上市 | 赛诺菲 | SOLIQUA 100/33 | fda | 2型糖尿病 | SANOFI-AVENTIS US | 2016-11-21 | 2型糖尿病 | 详情 | |
| Insulin lispro protamine biosimilar (Gan & Lee Pharmaceuticals) | 精蛋白锌重组赖脯胰岛素生物类似药(25R)（甘李药业） | 批准上市 | 甘李生物 | Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection(25R) | cfda | 糖尿病 | 2014-05-09 | 糖尿病 |
| 英文名称 | 研发代码 | 研发阶段 | 公司 | 适应症 | 临床试验 |
|---|---|---|---|---|---|
| Recombinant human insulin (HEC Pharm) | BLA 申请 | 广东东阳光药, 宜昌东阳光长江药业 | 糖尿病 | ||
| INS-061 | INS-061; HS-061 | 临床申请 | 上海恒瑞 | 糖尿病 | |
| Long-acting basal insulin analogue | 148-0287-A; Insulin-287; LAI-287; Long-acting basal insulin analogue; Long-acting-insulin-287; NN-1436; NN-1956; NNC-0148-0000-0287; NNC0148-0287 C; OI-287GT | 临床二期 | 诺和诺德 | 2型糖尿病 | 详情 |
| Insulin glargine biosimilar (YiChang HEC ChangJiang Pharmaceutical) | 临床三期 | 广东东阳光药, Lannett | 糖尿病 | ||
| Stem cell therapy (RejuvaCell) | 临床阶段不明 | RejuvaCell | 2型糖尿病 | ||
| Insulin lispro/Insulin glargine | 临床二期 | Adocia | 1型糖尿病, 2型糖尿病 | ||
| Insulin detemir biosimilar (Tonghua Dongbao Pharmaceutical) | 临床一期 | 通化东宝 | 糖尿病 | ||
| Insulin prandial injectable (Albireo Pharma) | VIAject-25; VIAject-7 | BLA 申请 | Albireo | 1型糖尿病, 糖尿病, 2型糖尿病 | |
| Insulin oral (Emisphere Technologies) | 临床二期 | Emisphere Technologies | 2型糖尿病 | ||
| Insulin aspart biosimilar (Gan & Lee) | BLA 申请 | 甘李生物 | 1型糖尿病, 2型糖尿病 | ||
| NN-1406 | NN-1406; NNC0143-0406; NNC0143-0406 A; PI-406 | 临床一期 | 诺和诺德 | 1型糖尿病, 2型糖尿病 | 详情 |
| Insulin glargine biosimilar(Shandong New Time Pharmaceutical) | BLA 申请 | 鲁南制药集团 | 糖尿病 | ||
| Insulin (Oramed Pharmaceuticals) | ORMD-0801 | 临床二期 | Oramed Pharmaceuticals, 合肥天汇孵化科技有限公司 | 1型糖尿病, 2型糖尿病 | 详情 |
| Bacitracin/Tranexamic acid | IPI-120 | 临床前 | Imprimis Pharmaceuticals | 外伤, 切口感染 | |
| Recobinant human proinsulin C peptide (Shanghai Newsummit/Shanghai Yizhong) | 临床一期 | 上海新生源医药 | 糖尿病性肾病 | ||
| Insulin lispro (Diasome Pharmaceuticals) | 临床二期 | Diasome Pharmaceuticals | 1型糖尿病 | ||
| Transdermal insulin patch (Dermisonics) | 临床一期 | Dermisonics, Encapsulation Systems, Transdermal Global | 糖尿病 | ||
| Insulin biosimilar (Hefei Tianmai Biotechnology) | 临床三期 | 合肥天麦生物科技发展有限公司 | 糖尿病 | ||
| Insulin adjustable basal (Biodel) | BIOD-809 | 临床一期 | Albireo | 糖尿病 | |
| Transdermal insulin patches (SK Chemicals) | 临床三期 | SK Chemicals | 1型糖尿病 | ||
| Insulin glargine biosimilar (Wanbang Biochemical) | 临床三期 | 万邦医药 | 2型糖尿病 | ||
| DM199 | DM-199; DM-99 | 临床二期 | DiaMedica | 中风, 2型糖尿病, 慢性肾病 | 详情 |
| PE-0139 | PE-0139 | 临床二期 | PhaseBio | 2型糖尿病 | 详情 |
| Ultra-rapid-acting insulin analogue (Albireo Pharma) | BIOD-238 | 临床一期 | Albireo | 1型糖尿病 | 详情 |
| Insulin transdermal (TransPharma Medical) | 临床阶段不明 | TransPharma Medical | 1型糖尿病, 2型糖尿病 | ||
| Transbuccal insulin (MidaSol) | MSRX-301; MSL-001; MTD-101 | 临床二期 | Midatech, Aquestive Therapeutics | 1型糖尿病 | |
| Basal insulin peglispro | LY-2605541,LY2605541 | 临床三期 | 礼来, 勃林格殷格翰 | 1型糖尿病, 2型糖尿病 | 详情 |
| Insulin mouth rinse (EastGate Biotech) | 临床三期 | Eastgate Biotech, Genome Pharmaceuticals | 1型糖尿病, 2型糖尿病, 阿尔茨海默病 | ||
| Recombinant human insulin biosimilar (Rechon Life Sciences) | 临床三期 | Rechon Life Science | 1型糖尿病 | ||
| KW-2450 | KW-2450 | 临床二期 | 协和发酵麒麟 | 乳腺癌 | 详情 |
| Recombinant insulin aspart biosimilar (Biogenomics) | 临床一期 | Biogenomics | 1型糖尿病, 2型糖尿病 | ||
| Ultra fast-acting insulin analogue | BC-106-Insulin-Lispro; BC-222-Insulin-Lispro | 临床三期 | Adocia, 礼来, 通化东宝 | 1型糖尿病, 2型糖尿病 | 详情 |
| Insulin receptor-regulating antibodies (XOMA) | X-129; XMet program; XMetA; XMetD;XMetS; XOMA-129 | 临床前 | Xoma | 糖尿病, 低血糖症 | |
| SAR-161271 | SAR 161271,SAR-161271,SAR161271 | 临床二期 | 赛诺菲 | 1型糖尿病 | 详情 |
| NN-344 | NN-344 | 临床一期 | 诺和诺德 | 1型糖尿病, 2型糖尿病 | |
| Insulin inhalation (Aerogen) | 临床二期 | Nektar | 糖尿病 | ||
| Insulin rectal (Oramed Pharmaceuticals) | ORMD-0802 | 临床一期 | Oramed Pharmaceuticals | 1型糖尿病 | |
| Oral insulin (Purede) | 临床阶段不明 | Puredel | 糖尿病 | ||
| Insulin glargine biosimilar (Tonghua Dongbao Pharmaceutical) | BLA 申请 | 通化东宝 | 糖尿病 | ||
| Human insulin biosimilar (Marvel Lifesciences) | BLA 申请 | Marvel LifeSciences Private | 糖尿病 | ||
| Fast-acting human insulin (Adocia) | BioChaperone-222; Hinsbet-U500 | 临床二期 | Adocia | 1型糖尿病 | |
| Recombinant human insulin (Nutrinia) | NTRA-9620,NTRA 9620,NTRA9620 | 临床三期 | Nutrinia | 短肠综合征 | 详情 |
| Insulin lispro biosimilar (Valin Technologies) | 临床前 | Valin Technologies | 糖尿病 | ||
| Insulin polysialic (Xenetic Biosciences) | SYN-20090110-RU; SYN-20090510-RU | 临床一期 | Lipoxen Technologies, SynBio, Xenetic Biosciences | 1型糖尿病, 中枢神经系统紊乱, 2型糖尿病 | |
| Insulin biosimilars (Bioton) | 临床阶段不明 | Bioton | 糖尿病 | ||
| Insulin inhalation (Andaris) | 临床一期 | Elan Corporation | 糖尿病 | ||
| Oral insulin-338-C10 | Insulin-338-GIPET-I; LAI-338; NN-1438; NN-1953; NNC0123-0338; OI-338GT; Oral insulin 338 C10 | 临床二期 | 诺和诺德, Merrion Pharmaceuticals | 1型糖尿病, 2型糖尿病 | 详情 |
| Ultra-rapid-acting insulin analogues (Albiero Pharma) | BIOD-250 | 临床一期 | Albireo | 1型糖尿病 | 详情 |
| Dulaglutide/Basal insulin Fc | 临床一期 | 礼来 | 糖尿病 | ||
| Linsitinib | ASP-7487; OSI-906; OSI-906AA,ASP7487,OSI906,OSI906AA | 临床三期 | 安斯泰来, 美国国立癌症研究所 | 肾上腺皮质癌 | 详情 |
| Insulin biosimilar (Valin Technologies) | Van-101,Van 101,Van101 | 临床三期 | Valin Technologies | 糖尿病 | |
| EX-1000 | EX1000,EX 1000 | 临床二期 | 诺和诺德 | 2型糖尿病 | 详情 |
| Insulin human (Pfizer) | HMR 4006 | 撤市 | 辉瑞, Nektar | 糖尿病 | 详情 |
| Insulin aspart biosimilar (Zhuhai United Laboratories) | BLA 申请 | 珠海联邦制药 | 1型糖尿病, 2型糖尿病 | ||
| INS-068 | INS-068,INS068; INS 068 | 临床一期 | 江苏恒瑞, 成都盛迪, 上海恒瑞 | 1型糖尿病, 2型糖尿病 | |
| Insulins (Halozyme) | Analog insulin-PH20; Aspart-PH20;Insulin-PH20; Lispro-PH20; rHuPH20/insulin | 临床二期 | Halozyme Therapeutics | 1型糖尿病, 2型糖尿病 | 详情 |
| Intranasal insulin (Johns Hopkins University) | 临床二期 | 约翰·霍普金斯大学 | HIV相关神经认知障碍, 多发性硬化症 | 详情 | |
| Insulin (Altea Therapeutics) | AT-1391 | 临床二期 | Nitto Denko | 1型糖尿病, 2型糖尿病 | |
| Human insulin/EDTA/Citrate/Magnesium sulfate (Biodel) | BIOD-123 | 临床二期 | Albireo | 1型糖尿病 | 详情 |
| MK-2640 | MK-2640,MK2640,MK 2640 | 临床一期 | 默沙东 | 1型糖尿病 | 详情 |
| recombinant human insulin | CKD-401,CKD 401,CKD401 | 临床三期 | Chong Kun Dang | 糖尿病 | |
| Insulin glargine biosimilar (Valin Technologies) | 临床一期 | Valin Technologies | 糖尿病 | ||
| AB-101 (Rezolute) | AB-101 | 临床一期 | IPR Pharmaceuticals, Rezolute, Xoma | 1型糖尿病 | 详情 |
| 重组赖精胰岛素（合肥天麦） | 临床三期 | 合肥天麦生物科技发展有限公司 | 糖尿病 | ||
| Insulin inhalation (MAP Pharmaceuticals) | MAP-0001 | 临床一期 | 艾尔建 | 1型糖尿病, 2型糖尿病 | |
| Insulin biosimilar (University of Montreal Health Centre) | 临床一期 | University of Montreal Health Centre | 青光眼 | 详情 | |
| Insulin oral (Diabetology) | DTY-001 | 临床二期 | Diabetology Ltd, USV | 1型糖尿病, 2型糖尿病 | |
| NN-1954 (Novo Nordisk) | NN-1954 | 临床一期 | 诺和诺德 | 1型糖尿病, 2型糖尿病 | 详情 |
| Concentrated ultra-rapid-acting insulin (Albireo Pharma) | BIOD-531 | 临床二期 | Albireo | 2型糖尿病 | 详情 |
| Insulin glargine biosimilar (Geropharm) | 临床三期 | GEROPHARM | 1型糖尿病, 2型糖尿病 | 详情 | |
| NKTR-034 | NKTR-034 | 临床一期 | Nektar | 糖尿病 | |
| BetaRx | 临床二期 | Vivorx Pharmaceuticals | 糖尿病 | ||
| HM-12460A | HM-12470; HM-12470A; SAR-440067 | 临床一期 | 韩美 | 1型糖尿病, 2型糖尿病 | 详情 |
| Insulin inhaled (Translational Research) | 临床一期 | Translational Research Ltd | 1型糖尿病 | ||
| Insulin inhalation (Abbott Laboratories) | KI-02212; KI-02-212 | 临床二期 | 雅培 | 糖尿病 | |
| Ultra fast-acting insulin lispro biosimilar (Perosphere) | URAL | 临床一期 | Perosphere | 1型糖尿病 | 详情 |
| AI-401 | AI-401 | 临床三期 | 国家糖尿病消化与肾脏病研究院 | 1型糖尿病 | 详情 |
| Pegylated recombinant human insulin (Chongqing Fujin Biomedical) | 临床一期 | 重庆富进生物医药 | 糖尿病 | ||
| Insulin lispro biosimilar (Wanbang Biopharma) | 临床三期 | 万邦医药 | 糖尿病 | ||
| CLX-0901 | CLX 0901 | 临床二期 | Theracos | 2型糖尿病 | |
| Insulin aspart biosimilar (Geropharm) | GP-40071; GP-40081 | 临床三期 | GEROPHARM | 糖尿病 | 详情 |
| Alirinetide | GM-6; GM-600; GM-602; GM-603; GM-604; GM-605; GM-606; GM-607; GM-608; GM-609 | 临床二期 | Genervon | 肌萎缩性脊髓侧索硬化症, 帕金森症, 缺血性脑卒中 | 详情 |
| HM-12470 | HM-12470A; SAR-440067; LAPS Insulin 115 | 临床一期 | 韩美, 赛诺菲 | 1型糖尿病, 2型糖尿病 | 详情 |
| Insulin inhalation (Lilly/Dura Pharmaceuticals) | 临床二期 | Dura Pharmaceuticals, 礼来 | 1型糖尿病, 2型糖尿病 | ||
| Insulin 320 | OI320GT; NN-1957 | 临床一期 | 诺和诺德 | 2型糖尿病 | 详情 |
| Insulin aspart biosimilar (Biocon/Mylan) | MYL-1601D | 临床三期 | Biocon, 迈兰制药 | 1型糖尿病 | |
| Semaglutide/Insulin 287 | NNC0148-0287sema | 临床一期 | 诺和诺德 | 2型糖尿病 | 详情 |
| Recombinant human insulin (Eastgate Biotech) | EGP-1214,EGP1214,EGP 1214 | 临床阶段不明 | Eastgate Biotech | 2型糖尿病, 糖尿病前期 | |
| XOMA-358 | XOMA-358; XOMA-247; XPA.15.247 | 临床二期 | Xoma | 高胰岛素血症, 低血糖症 | 详情 |
| Insulin inhaled (Coremed) | 临床一期 | CoreMed, 万邦医药, 复星医药 | 糖尿病 | ||
| MBL protein (Bridge BioResearch) | 临床一期 | Bridge BioResearch | 2型糖尿病 | ||
| Insulin (Coremed) | 临床一期 | CoreMed | 糖尿病 | ||
| Insulin intranasal (Marina Biotech) | 临床二期 | Marina Biotech, Autotelic | 2型糖尿病 | ||
| NN-1952 | NN-1952 | 临床一期 | 诺和诺德, Merrion Pharmaceuticals | 糖尿病 | 详情 |
| Basal insulin Fc (Eli Lilly) | 临床一期 | 礼来 | 糖尿病 | ||
| Insulin aspart biosimilar (Tonghua Dongbao Pharmaceutical) | 临床三期 | 通化东宝 | 糖尿病 | 详情 | |
| Insulin inhalation (Dong Sung/Biocon) | 临床二期 | Biocon BioPharmaceuticals, DongSung Pharm | 1型糖尿病 | 详情 | |
| Insuman U-400 | BLA 申请 | 赛诺菲 | 1型糖尿病 | ||
| AKP-11 | AKP-11,AKP11 | 临床二期 | Akaal Pharma | 斑块状银屑病 | |
| Insulin oral (Provalis) | 临床二期 | Provalis | 1型糖尿病, 2型糖尿病 | ||
| Insulin (transoral) (Noven Pharmaceuticals) | 临床一期 | 久光制药 | 1型糖尿病 | ||
| NP-01 | NP-01 | 临床一期 | Medesis Pharma SA | 2型糖尿病 | |
| Oral insulin (Orin Pharmaceuticals) | 临床二期 | Orin Pharmaceuticals | 2型糖尿病 | ||
| BIOD-125 (Biodel) | 临床一期 | Albireo | 1型糖尿病 | ||
| Hepatoselective insulin (BTG/King's College London) | 临床一期 | 伦敦国王学院, BTG plc | 1型糖尿病 |
